BRAF and melanoma: evaluated patients with BRAF-mutated melanoma brain metastases and BRAF kinase inhibitor use in conjunction with SRS and found that BRAF-mutated patients who received BRAF inhibitors following SRS had improved survival compared to patients who received it before (p<0.001) or concurrently (p = 0.007) (69).